GREENLAND MINES LTD Operating Expenses
GREENLAND MINES LTD (GRML) reported Operating Expenses of $5.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-17
- GREENLAND MINES LTD operating expenses for the quarter ending 2026-06-30 was $5.49M, a 190.14% increase year-over-year.
- GREENLAND MINES LTD operating expenses for the quarter ending 2026-03-31 was $9.51M, a 499.40% increase year-over-year.
- GREENLAND MINES LTD operating expenses for the quarter ending 2025-12-31 was $1.81M, a 2.08% decline year-over-year.
- GREENLAND MINES LTD operating expenses for the quarter ending 2025-09-30 was $1.85M, a 35.45% decline year-over-year.
- GREENLAND MINES LTD operating expenses for fiscal 2025 was $7.15M, a 28.99% increase from fiscal 2024.
- GREENLAND MINES LTD operating expenses for fiscal 2024 was $5.54M, a 777.56% increase from fiscal 2023.
- GREENLAND MINES LTD operating expenses for fiscal 2023 was $631.32K.
| Period end | Operating Expenses | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $5.49M 10-Q · filed 2026-08-17 | $15.00M 10-Q · filed 2026-08-17 | $16.82M derived: sum of 3 quarters · filed 2026-08-17 | $18.67M derived: sum of 4 quarters · filed 2026-08-17 | |
| 2026-03-31 | $9.51M 10-Q/A · filed 2026-08-14 | $11.33M derived: sum of 2 quarters · filed 2026-08-14 | $13.18M derived: sum of 3 quarters · filed 2026-08-14 | $15.07M derived: sum of 4 quarters · filed 2026-08-17 | |
| 2025-12-31 | $1.81M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | $3.67M derived: sum of 2 quarters · filed 2026-08-14 | $5.56M derived: sum of 3 quarters · filed 2026-08-17 | $7.15M 10-K/A · filed 2026-08-14 | |
| 2025-09-30 | $1.85M 10-Q · filed 2025-11-13 | $3.75M derived: sum of 2 quarters · filed 2026-08-17 | $5.33M 10-Q · filed 2025-11-13 | $7.18M derived: sum of 4 quarters · filed 2026-08-17 | |
| 2025-06-30 | $1.89M 10-Q · filed 2026-08-17 | $3.48M 10-Q · filed 2026-08-17 | $5.33M derived: sum of 3 quarters · filed 2026-08-17 | $8.20M derived: sum of 4 quarters · filed 2026-08-17 | |
| 2025-03-31 | $1.59M 10-Q/A · filed 2026-08-14 | $3.44M derived: sum of 2 quarters · filed 2026-08-14 | $6.31M derived: sum of 3 quarters · filed 2026-08-14 | $6.71M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2024-12-31 | $1.85M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | $4.72M derived: sum of 2 quarters · filed 2026-08-14 | $5.12M derived: sum of 3 quarters · filed 2026-08-14 | $5.54M 10-K/A · filed 2026-08-14 | |
| 2024-09-30 | $2.87M 10-Q · filed 2025-11-13 | $3.27M derived: sum of 2 quarters · filed 2025-11-13 | $3.69M 10-Q · filed 2025-11-13 | $4.05M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $395.61K 10-Q · filed 2025-08-18 | $817.65K 10-Q · filed 2025-08-18 | $1.18M derived: sum of 3 quarters · filed 2025-08-18 | $1.30M derived: sum of 4 quarters · filed 2025-08-18 | |
| 2024-03-31 | $672.04K 10-Q · filed 2025-05-15 | $782.78K derived: sum of 2 quarters · filed 2025-05-15 | $906.51K derived: sum of 3 quarters · filed 2025-05-15 | $1.15M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $110.73K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $234.47K derived: sum of 2 quarters · filed 2025-03-31 | $478.72K derived: sum of 3 quarters · filed 2025-03-31 | $631.32K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $123.74K 10-Q · filed 2024-11-19 | $367.99K derived: sum of 2 quarters · filed 2024-11-19 | $520.59K 10-Q · filed 2024-11-19 | ||
| 2023-06-30 | $244.25K 10-Q · filed 2024-08-19 | $396.85K 10-Q · filed 2024-08-19 | |||
| 2023-04-30 | $153.09K 10-Q · filed 2024-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |